HCA Healthcare shares slide as 2026 guidance held flat

What moved the stock

HCA Healthcare (NYSE: HCA) shares came under pressure after a Barclays downgrade and as investors digested the company’s first-quarter 2026 update, which triggered a sharp earnings-day reaction. The stock fell 8.77% on April 24, 2026, described as its steepest single-day drop in more than a year. Separate market updates also described the stock as down around 6.1% at one point during the session, and down 8.49% to 8.7% in other readings.

The selling followed what several summaries framed as a “reset in expectations”: results were broadly solid on revenue and earnings per share, but a key profitability measure missed estimates and full-year guidance was reaffirmed rather than raised.

Price, volume, and intraday levels

Trading volume was reported at 894,685 shares, below a stated daily average of about 1.5 million shares. One tape showed a print at $111.23, down $11.88 or 2.81%. Other readings put the stock around $132.46 (also shown as “Aktueller Kurs: $132,46”) and $133.12 to $133.48 during the day.

The stock traded as low as $122.19, noted as the lowest intraday level since October 2025 in one market recap. Another data point said it would be the lowest close since Oct. 21, 2025 if it finished near the day’s levels.

Q1 FY2026: headline numbers investors focused on

HCA reported Q1 2026 revenue of $19.11 billion and adjusted EPS of $1.15, both described as meeting Wall Street consensus estimates. The pressure point was adjusted EBITDA of $1.80 billion, which was cited as below an expected $1.85 billion.

Several write-ups also pointed to utilization trends. HCA said it did not see a typical seasonal lift in volumes, with respiratory-related admissions and respiratory-related ER visits materially lower year over year, and it referenced a January winter storm that hurt volumes in certain markets.

Guidance: reaffirmed, not raised

A central trigger for the selloff was management’s decision to reaffirm full-year 2026 guidance “without change,” rather than lifting it. The company reaffirmed 2026 diluted EPS guidance of $19.10 to $11.50.

On the top line, HCA reaffirmed full-year 2026 revenue guidance of $16.5 billion to $10.0 billion. It also reaffirmed adjusted EBITDA guidance of $15.55 billion to $16.45 billion.

Some commentary suggested the market had been positioned for a raise, and treated a “guide-hold” as a near-miss.

Policy and cost items highlighted by investors

Investors had also been monitoring policy-related headwinds tied to Affordable Care Act exchange dynamics. One summary noted a promised effort to offset a headwind of $1.6 billion to $1.9 billion related to the expiration of enhanced premium tax credits.

The same context cited a $1.4 billion cost-savings program and an authorization for $10.0 billion of share repurchases. Another recap said guidance assumptions include public policy developments and potential impacts tied to health insurance exchange reforms and the expiration of enhanced premium tax credits.

What management said about volumes and one-offs

Across the reports, management commentary was characterized as treating the quarter’s weakness as driven by temporary factors rather than a structural shift. Weather effects and a weak flu season were repeatedly referenced as the main operational drags.

One report added that some headwinds were mostly offset by recognition of certain Medicaid supplemental programs that were not included in initial 2026 guidance.

Sector context and relative performance

In one sector snapshot, the Healthcare Services & Equipment sector was down 0.81%, while HCA underperformed. The same list of high-turnover names showed UnitedHealth Group (UNH) down 0.40%, HCA down 8.59%, and Hims & Hers Health (HIMS) up 9.33%.

Another recap said HCA was the second-worst performer in the S&P 500 at one point in the session.

Technical signals cited in the coverage

One technical summary flagged a MACD (12,26,9) of -6.38 as a sell signal, alongside RSI at 39.21 (described as neutral) and Williams %R at -81.38 (described as oversold). These indicators were presented as monitoring tools rather than fundamental drivers.

Key numbers at a glance

Market impact: what investors recalibrated

The immediate market impact was a repricing of near-term expectations. Even with revenue and adjusted EPS characterized as in line, the adjusted EBITDA shortfall and unchanged full-year guidance dominated investor attention.

The coverage also pointed to softer seasonal utilization, especially respiratory-related trends, as a driver of concern for growth assumptions. At the same time, HCA was still described as a cash-generating hospital operator, and the quarter was framed by several summaries as influenced by temporary operational factors like weather and flu season dynamics.

Why this matters for HCA watchers

For a large hospital operator, small changes in utilization and operating leverage can have an outsized effect on profitability metrics like EBITDA. That is why a roughly $1.05 bn gap versus an expected $1.85 bn adjusted EBITDA number drew attention despite other lines landing near consensus.

Separately, reaffirmed guidance kept the focus on the balance between policy-related uncertainty and the company’s stated mitigation levers, including cost actions and capital returns.

Conclusion

HCA’s April 24 selloff reflected a market that wanted a stronger profitability print and a guidance lift. Instead, investors received an EBITDA miss and an unchanged 2026 outlook, with management citing weather and atypical seasonal patterns. The next major checkpoint for sentiment will be subsequent updates on volumes and whether results track within the reaffirmed FY2026 ranges for EPS, revenue, and adjusted EBITDA.